Pancragen

What is it?

Pancragen is a Khavinson tetrapeptide for the pancreas — part of the digestive/hepatic corner of the Khavinson short-peptide bioregulator family, alongside Ovagen and Livagen. It’s a framework-level compound only: the metabolic/beta-cell angle is an interesting hook if it ever gets real data, but right now there is none.

What does it do in my body?

Claimed mechanism: like the rest of the Khavinson family, Pancragen is proposed to act at gene-promoter regions in pancreatic cells, modulating proteins involved in insulin secretion and beta-cell maintenance. This is the family-wide theoretical mechanism applied to the pancreas as the target organ — there is no Pancragen-specific mechanistic study to cite.

How can it help me?

• Where the science stands: Site tier Anecdotal, 0 studies cited — “no published clinical studies were found on PubMed”

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

No adverse-event data exists for Pancragen. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and a peptide with zero published studies is an especially easy target for mislabeling since there’s no literature to check a seller’s claims against at all. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Pancragen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.

Typical dosing

Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.

Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.

There is no dosing or cycling data specific to Pancragen — with zero published studies, there is no dose-finding work of any kind. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Pancragen specifically.

What should I avoid combining — and what's synergistic?

Pancragen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

Where do people source this?